[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100345538":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":29,"responsibleParty":46,"collaborators":48,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":11,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University Hospital, Ghent","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tracer injection","EXPERIMENTAL",null,[13],"Other: ICG-nanocoll (indocyanine green coupled to the human albumin colloidal particle nanocoll)",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"ICG-nanocoll (indocyanine green coupled to the human albumin colloidal particle nanocoll)","Under laparoscopic control, 2.0 ml of ICG-nanocoll will be injected into the subserosa at four quadrants around the tumor. Directly after injection, near infrared (NIR) fluorescence images (Olympus, Tokyo, Japan) will be acquired. SLNs will be identified and marked.",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},"Wim Ceelen","CONTACT","+32(0)93326251","wim.ceelen@ugent.be",{"name":26,"role":22,"phone":27,"phoneExt":11,"email":28},"Sarah Cosyns","+32(0)93321562","sarah.cosyns@ugent.be",[30],{"facility":31,"status":32,"city":33,"state":11,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Ghent University Hospital","RECRUITING","Ghent","9000","Belgium","BE",{"type":38,"coordinates":39},"Point",[40,41],3.71667,51.05,{"lat":41,"lon":40},[44,45],{"name":21,"role":22,"phone":23,"phoneExt":11,"email":24},{"name":26,"role":22,"phone":11,"phoneExt":11,"email":11},{"type":47,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[49],{"name":50,"class":6},"Kom Op Tegen Kanker","100345538","minimally-invasive-colon-cancer-surgery-through-immunomics-and-optical-mapping-of-the-sentinel-lymph-node-100345538",false,"NCT03779009","Minimally INvasive Colon Cancer Surgery Through IMmunomics and Optical Mapping of the Sentinel Lymph Node.","MINIMAL","Inclusion Criteria:\n\n* Tumor type: proven adenocarcinoma of the colon\n* Extent of disease (AJCC 7th edition): clinically node negative (stage II) non-metastatic colon cancer\n* Locally resectable disease\n* Adequate mental faculty, allowing to understand the proposed treatment protocol and provide informed consent\n* Laboratory data\n\n  * Serum creatinine ≤ 1.5 mg\u002Fdl or a calculated GFR ≥ 60 mL\u002Fmin\u002F1.73 m2\n  * Serum total bilirubin ≤ 1.5 mg\u002Fdl, except for known Gilbert's disease\n  * Platelet count \\> 100,000\u002Fµl\n  * Hemoglobin \\> 9g\u002Fdl\n  * Neutrophil granulocytes \\> 1,500\u002Fml\n  * International Normalized Ratio (INR) ≤ 2\n* Absence of alcohol and\u002For drug abuse\n* No inclusion in other clinical trials interfering with the study protocol\n* No concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy\n* Absence of any severe organ insufficiency\n* No pregnancy or breast feeding\n* Adequate contraception in fertile patients\n* Written informed consent\n\nExclusion Criteria:\n\n* Node positive and\u002For metastatic disease\n* Locally unresectable disease\n* Medically unfit patients (Karnofsky index \\\u003C 70%)\n* Allergies to any of the procedural substances (allergy to iodides, hypersensitivity to products containing human albumin)","ALL","18 Years",{"count":61,"type":62},70,"ESTIMATED","INTERVENTIONAL",[65],"NA","The project investigates the feasibility of laparoscopic fluorescent imaging for the intraoperative detection of the sentinel lymph node (SLN) in colon cancer patients. In addition, the topology of immunological and microenvironmental changes in normal and invaded lymph nodes (LN's) will be correlated to the LN location (anatomical mapping).",[68,69],"Colon Cancer","Sentinel Lymph Node","2024-09-03",{"date":72,"type":73},"2024-09-19","ACTUAL",{"date":75,"type":73},"2018-03-01",{"date":77,"type":62},"2025-12-31",{"name":5,"class":6},1]